| Identification | Back Directory | [Name]
CP 100356 | [CAS]
142716-85-6 | [Synonyms]
CP 100356
CP 100356 hydrochloride
2-Quinazolinamine, 4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxy-
4-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-N-2[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxy-2-quinazolinaminehydrochloride | [Molecular Formula]
C31H36N4O6 | [MDL Number]
MFCD00911858 | [MOL File]
142716-85-6.mol | [Molecular Weight]
560.64 |
| Chemical Properties | Back Directory | [Melting point ]
206-210°C | [Boiling point ]
741.9±70.0 °C(Predicted) | [density ]
1.238±0.06 g/cm3(Predicted) | [storage temp. ]
Desiccate at RT | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
7.79±0.70(Predicted) | [color ]
Off-White to Light Tan |
| Hazard Information | Back Directory | [Uses]
CP-100356 is a specific inhibitor of MDR1 (P-Gp), the protypical ABC transporter. CP-100356 also inhibits prazosin transport in human breast cancer resistance protein (BCRP)-transfected MDCKII cells, suggesting that it acts as a dual inhibitor. CP-100356 does not inhibit multidrug resistance-associated protein 2 (MPR2 IC50 >15 mM). |
|
|